Nia Adeniji

6PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 14, 2026
A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

|Dec 16, 2022
MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages.

Renumathy Dhanasekaran, Aida S Hansen, Jangho Park

|Sep 17, 2021
Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.

Nia Adeniji, Renumathy Dhanasekaran

|Oct 24, 2020
Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.

Nia Adeniji, Vinodhini Arjunan, Vijay Prabhakar

|Sep 23, 2020
Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience.

Atoosa Rabiee, Brett Sadowski, Nia Adeniji

|Jan 15, 2020
MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity.

Renumathy Dhanasekaran, Virginie Baylot, Minsoon Kim

Pageof 1

Frequent Collaborators

5 joint publications

Renumathy Dhanasekaran

2 joint publications

Ian Lai

2 joint publications

Jangho Park

2 joint publications

Dean W Felsher